Ortho Molecular Products to Onboard Clinicians to HANS AI Platform
Ortho Molecular Products has become the exclusive onboarding partner for HANS, an AI clinical co-pilot designed for functional and integrative medicine. The partnership aims to help clinicians manage documentation, patient plans and complex clinical workflows.
- Ortho Molecular Products is HANS's exclusive onboarding partner.
- HANS is built for functional and integrative medicine workflows.
- In beta, HANS drafted a complete SOAP note in a median 3.2 minutes.
- The platform's knowledge library contains more than 5,000 citations across 109 Clinical Intelligence Guides.
- HANS is now available in the U.S.
Partnership targets administrative workload
Ortho Molecular Products and HANS.FM announced the partnership on Nov. 10, 2026, naming Ortho Molecular Products the exclusive onboarding partner for HANS. The platform is designed around the multi-system workflows used in functional medicine, where practitioners provide highly personalized care.
According to the companies, clinicians typically spend 30-60 minutes per patient on documentation and visit preparation, and up to 60-90 minutes on the most complex cases. In beta, HANS recorded a median time of 3.2 minutes to draft a complete SOAP note and approximately 29 seconds to generate a patient plan.
Ortho Molecular Products said its onboarding services will give clinicians support as they begin using the platform. The company has worked with practitioners in functional and integrative medicine for nearly 40 years, according to the announcement.
HANS is built for functional medicine workflows
HANS was developed alongside practicing clinicians and uses a physician-developed, closed-loop functional medicine knowledge library. The library contains more than 5,000 citations across 109 Clinical Intelligence Guides.
The platform is designed to support specialized laboratories, personalized protocols and multi-system cases. Its stated functions include pre-consultation synthesis, longitudinal lab cross-correlation, draft SOAP notes and protocol management.
Unlike open-ended AI tools that draw from broad internet sources, HANS provides transparency behind its outputs, according to the companies. Practitioners can review or override AI-generated information before it enters a patient chart. This workflow is intended to keep clinicians involved in decisions made with the system.
“Our mission is to reduce the cognitive and administrative burden on practitioners with technology that supports, rather than replaces, clinical judgment,” said Andrew Le, MD, CEO of HANS.
Availability and implications for clinicians
HANS is now available in the U.S. and is supported by Ortho Molecular Products' exclusive onboarding services. The companies direct prospective users to HANS.fm for information about available plans, pricing and product capabilities.
Gary Powers, CEO at Ortho Molecular Products, said the partnership extends the company's commitment to functional and integrative medicine. “Serving as the exclusive onboarding partner of HANS extends our commitment, giving clinicians the infrastructure they need to work more efficiently and helping them keep focus on their patients' outcomes,” Powers said.
For practitioners, the announcement presents HANS as a specialized alternative to general-purpose AI tools, with workflows and clinical references aimed at functional medicine. The companies say the intended result is less time spent on administrative tasks and more capacity for patient care, while leaving clinical judgment with practitioners.
